Discontinued ProductUnfortunately Bucindolol (Cat. No. 2658) has been withdrawn from sale for commercial reasons.
Non-selective β-adrenoceptor antagonist with additional α1-adrenoceptor blocking activity. Ki values are 1.61, 1.20 and 68.9 nM for β1-, β2- and α1-adrenoceptors respectively. Also acts as a weak 5-HT2A/2B antagonist. Displays vasodilatory and antihypertensive actions.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 363.45. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.75 mL||13.76 mL||27.51 mL|
|5 mM||0.55 mL||2.75 mL||5.5 mL|
|10 mM||0.28 mL||1.38 mL||2.75 mL|
|50 mM||0.06 mL||0.28 mL||0.55 mL|
References are publications that support the products' biological activity.
Watts et al (2000) Interaction of the [beta] adrenergic receptor antagonist bucindolol with serotonergic receptors. J.Cardiovasc.Pharmacol. 35 29 PMID: 10630730
Ponicke et al (2002) Differential effects of bucindolol and carvedilol on noradrenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats. J.Pharmacol.Exp.Ther. 301 71 PMID: 11907159
View Related Products by Product Action
Keywords: Bucindolol, supplier, α1-adrenoceptor, beta1-adrenoceptor, b1-adrenoceptor, b1-adrenergic, β1-Adrenergic, beta1-Adrenergic, α2-adrenoceptor, beta2-adrenoceptor, β2-adrenergic, α2-adrenergic, beta2-adrenergic, b2-adrenoceptor, antagonists, Receptors, Non-Selective, MJ, MJ, 13105, Non-selective, Adrenergic, Beta, Receptors, Non-selective, Adrenergic, Beta, Receptors, Tocris Bioscience
Citations for Bucindolol
Citations are publications that use Tocris products.
Currently there are no citations for Bucindolol.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.